Severe asthma remaining well‐controlled after mepolizumab discontinuation: A case report and literature review

Abstract Mepolizumab, a humanized anti‐IL‐5 monoclonal antibody used for severe asthma, results in a reduced rate of asthma exacerbation, improved lung function, reduced oral corticosteroid use, and improved quality of life. A 62‐year‐old man using high‐dose inhaled corticosteroid visited our hospit...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Takahiro Matsuyama, Yuya Tomioka, Hiromi Matsuyama, Yusuke Kamenohara, Kengo Tanigawa, Yoichi Dotake, Yoko Hagihara, Koichi Takagi, Kentaro Machida, Hiromasa Inoue
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2023-06-01
coleção:	Respirology Case Reports
Assuntos:	asthma control eosinophil mepolizumab severe asthma
Acesso em linha:	https://doi.org/10.1002/rcr2.1158
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!